APA
Click to copy
Günther, G., van Leth, F., Altet, N., Dedicoat, M., Duarte, R., Gualano, G., … Lange, C. (2015). Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. The International Journal of Tuberculosis and Lung Disease.
Chicago/Turabian
Click to copy
Günther, G., F. van Leth, N. Altet, M. Dedicoat, R. Duarte, G. Gualano, H. Kunst, et al. “Beyond Multidrug-Resistant Tuberculosis in Europe: a TBNET Study.” The International Journal of Tuberculosis and Lung Disease (2015).
MLA
Click to copy
Günther, G., et al. “Beyond Multidrug-Resistant Tuberculosis in Europe: a TBNET Study.” The International Journal of Tuberculosis and Lung Disease, 2015.
BibTeX Click to copy
@article{g2015a,
title = {Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.},
year = {2015},
journal = {The International Journal of Tuberculosis and Lung Disease},
author = {Günther, G. and van Leth, F. and Altet, N. and Dedicoat, M. and Duarte, R. and Gualano, G. and Kunst, H. and Muylle, I. and Spînu, V. and Tiberi, Simon and Viiklepp, P. and Lange, C.}
}
The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).